InflaRx N.V. (IFRX) News
Filter IFRX News Items
IFRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IFRX News Highlights
- For IFRX, its 30 day story count is now at 4.
- Over the past 6 days, the trend for IFRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about IFRX are III, PG and NOV.
Latest IFRX News From Around the Web
Below are the latest news stories about INFLARX NV that investors may wish to consider to help them evaluate IFRX as an investment opportunity.
InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerInflaRx N.V. (IFRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma GangrenosumMulti-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S.PG is a rare and debilitating autoimmune skin disease characterized by painful ulcers that can rapidly progress JENA, Germany, Nov. 06, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that the first patient has been dosed in its P |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to dive into the biggest pre-market stock movers for Friday with all the shares investors will want to keep an eye on today! |
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business UpdateSingle ascending dose (SAD) Phase I data confirm best-in-class potential of orally available C5aR inhibitor INF904; multiple ascending dose (MAD) part ongoingSix clinical sites initiated; first patients screened in Phase III trial of vilobelimab in pyoderma gangrenosum (PG)FDA regulatory pathway towards BLA in broader acute respiratory distress syndrome (ARDS) indication discussed in encouraging FDA Type C meetingMAA for vilobelimab for treatment of SARS-CoV-2 induced septic ARDS in critically i |
12 Best German Stocks To Buy NowIn this piece, we will take a look at the 12 best German stocks to buy now. If you want to skip our overview of the German economy and how it has struggled as of late, then check out 5 Best German Stocks To Buy Now. The outbreak of the Russian invasion of Ukraine upended […] |
Loss-Making InflaRx N.V. (NASDAQ:IFRX) Expected To Breakeven In The Medium-TermInflaRx N.V. ( NASDAQ:IFRX ) is possibly approaching a major achievement in its business, so we would like to shine... |
We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
InflaRx (IFRX) Skyrockets 110% in Six Months: Here's WhyShares of InflaRx (IFRX) show an upward trajectory after it obtained authorization for its first-ever marketed drug, which is approved for the treatment of critically ill COVID-19 patients. |
Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & MoreRegulatory updates from Fibrogen (FGEN) and Bristol Myers (BMY) are in focus in the biotech sector. |
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)MAA for vilobelimab was submitted in JulyMAA has been validated by EMA and is now under reviewRegulatory submission based on pivotal data from PANAMO Phase III trialCompany announces attendance at upcoming scientific and investor events JENA, Germany, Aug. 30, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that the Company has submitted a Marketing Authorization Application ( |